Bhavesh Mohan Lal, MD, UAMS College of Medicine, Little Rock, Arkansas, reviews a study designed to investigate the effects of prior exposure to BCMA-targeting agents on outcomes with…
Praneeth Reddy Sudalagunta, PhD, applied research scientist, Moffitt Cancer Center, Tampa, Florida, discusses the differential effects of bridging therapy on the immune microenvironment as well as outcomes with…
A new analysis published in European Urology suggests that the risk window of recurrence for surgically treated renal cell carcinoma (RCC) may be longer than previously thought. Hoping…
Published final results of the DeCOG-SLT trial add evidence that patients who have a positive sentinel lymph-node biopsy, and have immediate complete lymph node dissection, do not achieve…
There have been many changes in the treatment landscape of stage II and stage III melanoma over the past decade. This article takes a look at the benefits…
Determining which patients are most likely to benefit from BRAF-targeted therapies was the topic of a recent review by Anna C. Pavlick, DO, MBA, of New York University…
Determining which patients are most likely to benefit from BRAF-targeted therapies was the topic of a recent review in ASCO Educational Book by Anna C. Pavlick, DO, MBA,…
A preliminary clinical study looking at previously untreated metastatic melanoma showed promising results when treating with the combination of an IL-2 signaling agonist and nivolumab. Primary trial objectives…
Early data from the phase III CheckMate 067 trial, reported in September 2017, showed that patients with advanced melanoma treated with nivolumab, with or without ipilimumab, maintained their quality…
Authors of an article published in Clinical Genitourinary Cancer analyzed aspects of laparoscopic treatment of renal cell cancer during pregnancy. Led by Lucio Dell’Atti of the Department of…
A retrospective study’s multivariate analysis suggests that in the treatment of early invasive melanoma, the use of Mohs micrographic surgery is associated with better outcomes when compared with…
Despite an abundance of preclinical evidence supporting the treatment strategy of combining an IDO1 inhibitor with anti-PD-1/PD-L1 immunotherapy, the results of a recent clinical trial were unable to confirm…
